Angulo Gonzalez David 4

What Happened

• David Angulo, CEO of SCYNEXIS, acquired 108,695 shares of common stock in a private placement that closed April 1, 2026. The purchase included accompanying warrants to buy up to 108,695 additional shares. The combined price per Share plus accompanying Common Warrant was $0.92, for a total cash outlay of roughly $100,000.
• The filing shows a parallel derivative entry for the Common Warrants (the right to buy additional shares) issued to Mr. Angulo as part of the same private placement.

Key Details

• Transaction date: purchase agreement dated March 30, 2026; closing and acquisition dated April 1, 2026. Form 4 filed April 2, 2026 (timely).
• Price: $0.92 per Share with accompanying Common Warrant; total ≈ $99,999.40.
• Shares owned after transaction: not specified in the Form 4 disclosure.
• Notable footnotes:
  • F1: Private placement with accredited investors, including the reporting person; Shares + Common Warrants issued on April 1, 2026.
  • F2: Filing notes 4,000 shares acquired earlier under the company’s 2014 ESPP (March 5, 2026).
  • F3: Common Warrants become exercisable only after stockholder approval to increase the company’s authorized common shares.
  • F4: Warrants expire on the earlier of five years from issue or 30 days after the issuer publicly releases topline Week‑48 Phase 2 trial data for SCY‑770.
• Transaction code: P = Purchase; derivative (warrant) reported separately.

Context

• The transaction is a direct cash purchase in a private placement rather than an exercise/sale. The attached warrants are a derivative right to buy shares later if and when certain corporate approvals occur.
• For retail investors: purchases by insiders can be seen as positive informational signals, but filings are factual records only — they do not prove future company performance.